$8.67
0.141.64%
At close: -
$8.69
0.020.23%
After Hours: 7:51 PM EDT
Comments
Loading...
Aurinia Pharmaceuticals Insider Trading Activity | NASDAQ:AUPH | Benzinga
Track the latest Aurinia Pharmaceuticals insider trading activity. Stay informed on recent buys, sells, and market impact for Aurinia Pharmaceuticals stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Aurinia Pharmaceuticals Inc Insiders Doing?
At Aurinia Pharmaceuticals Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have reported selling a total of 8.31K shares worth $68.35K, meanwhile, insiders have reported buying a total of 1.60M shares for a total value of $12.71M.
Notable Recent Insider Buys and Sales
- On March 4, 2025, Kevin Tang, the company's - purchased 1.6M shares for $7.95 each.
- On March 7, 2025, Greg Keenan, the company's CHIEF MEDICAL OFFICER sold 8.31K shares for $8.23 each.
Ownership Statistics for Aurinia Pharmaceuticals Inc
Shares Outstanding
137.339M
Insider Shares Owned
4.768M
Insider Percentage Owned
3.47%
Institutional Shares Held
23.161M
Institutional Percentage Held
16.9%
| Mar 07, 2025 | Greg Keenan | CHIEF MEDICAL OFFICER | -8.30K | $8.23 | -$68.35K | SELL | -5.13% | 153.48K | Mar 07 | View |
| Mar 04, 2025 | Peter Greenleaf | CHIEF EXECUTIVE OFFICER | 263.89K | $7.96 | -$2.87M | GRANT | 17.30% | 1.79M | Feb 28 - Mar 04 | View |
| Mar 04, 2025 | Greg Keenan | CHIEF MEDICAL OFFICER | 50.34K | $8.00 | -$97.91K | GRANT | 45.17% | 161.79K | Feb 28 - Mar 03 | View |
| Mar 04, 2025 | Joseph M Miller | CHIEF FINANCIAL OFFICER | 78.16K | $7.96 | -$939.61K | GRANT | 15.66% | 577.36K | Feb 28 - Mar 04 | View |
| Mar 04, 2025 | Stephen P Robertson | EVP, GENERAL COUNSEL | 64.03K | $7.96 | -$975.22K | GRANT | 14.38% | 509.28K | Feb 28 - Mar 04 | View |
| Mar 04, 2025 | Matthew Maxwell Donley | CHIEF OPERATING OFFICER | 93.45K | $7.96 | -$994.42K | GRANT | 15.92% | 680.47K | Feb 28 - Mar 04 | View |
| Mar 04, 2025 | Kevin Tang | — | 1.60M | $7.95 | $12.71M | BUY | 18.98% | 10.03M | Feb 28 - Mar 04 | View |
| Dec 09, 2024 | Kevin Tang | — | 1.20M | $9.02 | $10.82M | BUY | 16.60% | 8.43M | Dec 05 - Dec 09 | View |
| Nov 12, 2024 | Jeffrey A. Bailey | DIRECTOR | 13.36K | $8.43 | -$38.42K | SELL-OPTIONS | ∞ | 13.36K | Nov 08 - Nov 11 | View |
| Nov 12, 2024 | Karen L Smith | DIRECTOR | 12.67K | $8.43 | -$44.18K | SELL-OPTIONS | ∞ | 12.67K | Nov 08 - Nov 11 | View |
| Aug 08, 2024 | Scott Habig | CHIEF COMMERCIAL OFFICER | -18.25K | $5.31 | -$96.90K | SELL | -3.85% | 456.34K | Aug 06 | View |
| May 22, 2024 | Brinda Balakrishnan | DIRECTOR | -520.00 | $5.74 | -$2.98K | SELL | -2.88% | 17.52K | May 21 | View |
| May 22, 2024 | Daniel Billen | DIRECTOR | -5.25K | $5.74 | -$30.15K | SELL | -15.73% | 28.14K | May 21 | View |
| May 22, 2024 | David R.W. Jayne M.D. | DIRECTOR | -4.95K | $5.74 | -$28.39K | SELL | -10.03% | 44.36K | May 21 | View |
| May 22, 2024 | Jill Leversage | DIRECTOR | -5.61K | $5.74 | -$32.20K | SELL | -30.28% | 12.92K | May 21 | View |
| May 22, 2024 | Hector MacKayDunn | DIRECTOR | -5.63K | $5.74 | -$32.32K | SELL | -23.24% | 18.59K | May 21 | View |
| Mar 07, 2024 | Peter Greenleaf | CHIEF EXECUTIVE OFFICER | -126.98K | $5.60 | -$711.09K | SELL | -7.70% | 1.52M | Mar 06 | View |
| Mar 07, 2024 | Joseph M Miller | CHIEF FINANCIAL OFFICER | -34.81K | $5.60 | -$194.94K | SELL | -6.56% | 495.93K | Mar 06 | View |
| Mar 07, 2024 | Matthew Maxwell Donley | EVP, OPS & STRATEGY | -40.66K | $5.51 | -$224.06K | SELL | -6.51% | 584.07K | Mar 06 | View |
| Mar 07, 2024 | Scott Habig | CHIEF COMMERCIAL OFFICER | -17.78K | $5.60 | -$99.55K | SELL | -3.61% | 474.59K | Mar 06 | View |
| Mar 07, 2024 | Stephen P Robertson | EVP, GENERAL COUNSEL | -57.74K | $5.60 | -$323.37K | SELL | -11.51% | 443.82K | Mar 06 | View |
| Feb 29, 2024 | Volker Knappertz | EVP, RESEARCH AND DEVELOPMENT | -4.93K | $6.10 | -$30.07K | SELL | -1.52% | 319.13K | Feb 27 | View |
| Feb 22, 2024 | Volker Knappertz | EVP, RESEARCH AND DEVELOPMENT | -25.15K | $5.48 | -$137.80K | SELL | -7.20% | 324.06K | Feb 20 | View |
| Feb 22, 2024 | Scott Habig | CHIEF COMMERCIAL OFFICER | 179.65K | $5.48 | -$86.95K | GRANT | 57.45% | 492.36K | Feb 20 | View |
| May 23, 2023 | David R.W. Jayne M.D. | DIRECTOR | 9.31K | $11.26 | -$98.33K | SELL-OPTIONS | 23.28% | 49.31K | May 18 - May 23 | View |
| May 23, 2023 | Joseph P Hagan | DIRECTOR | 8.46K | $10.58 | -$2.88K | SELL-OPTIONS | 241.74% | 11.96K | May 18 - May 19 | View |
| May 23, 2023 | Daniel Billen | DIRECTOR | 13.39K | $11.26 | -$52.36K | SELL-OPTIONS | 66.97% | 33.39K | May 18 - May 23 | View |
| May 23, 2023 | Hector MacKayDunn | DIRECTOR | 13.22K | $11.26 | -$54.25K | SELL-OPTIONS | 120.23% | 24.23K | May 18 - May 23 | View |
| May 23, 2023 | Jill Leversage | DIRECTOR | 13.23K | $11.26 | -$54.22K | SELL-OPTIONS | 249.58% | 18.53K | May 18 - May 23 | View |
| Mar 06, 2023 | George M. Milne Jr., Ph.D. | DIRECTOR | 20.00K | $8.91 | $178.28K | BUY | 40.00% | 70.00K | Mar 02 | View |
| Mar 06, 2023 | Joseph M Miller | CHIEF FINANCIAL OFFICER | 218.13K | $8.94 | -$100.99K | GRANT | 192.88% | 331.21K | Mar 02 | View |
| Mar 06, 2023 | Stephen P Robertson | EVP, GENERAL COUNSEL | 185.41K | $8.94 | -$173.45K | GRANT | 157.18% | 303.36K | Mar 02 | View |
| Mar 06, 2023 | Peter Greenleaf | CHIEF EXECUTIVE OFFICER | 634.66K | $8.94 | -$292.79K | GRANT | 182.21% | 982.97K | Mar 02 | View |
| Nov 23, 2022 | Matthew Maxwell Donley | EX VP, INTERNAL OPERATIONS | 10.00K | $4.66 | $46.60K | BUY | 55.78% | 27.93K | Nov 21 | View |
| Nov 14, 2022 | Scott Habig | CHIEF COMMERCIAL OFFICER | 5.00K | $5.01 | $25.07K | BUY | ∞ | 5.00K | Nov 09 | View |
| Nov 09, 2022 | Michael Robert Martin | CHIEF BUSINESS OFFICER | 30.00K | $5.16 | $154.80K | BUY | 50.41% | 89.51K | Nov 07 | View |
| Mar 11, 2022 | Hector MacKayDunn | DIRECTOR | 5.00K | $11.00 | $54.98K | BUY | 83.33% | 11.00K | Mar 09 | View |
| Mar 08, 2022 | George M. Milne Jr., Ph.D. | DIRECTOR | 5.00K | $10.82 | $54.10K | BUY | 11.11% | 50.00K | Mar 04 | View |
| Mar 04, 2022 | Michael Robert Martin | CHIEF BUSINESS OFFICER | 3.65K | $12.01 | -$58.24K | GRANT | 6.54% | 59.51K | Mar 02 | View |
| Mar 04, 2022 | Matthew Maxwell Donley | EX VP, INTERN'L OPERATIONS | 5.45K | $12.01 | -$36.65K | GRANT | 50.56% | 16.22K | Mar 02 | View |
| Mar 04, 2022 | Joseph M Miller | CHIEF FINANCIAL OFFICER | 5.44K | $12.01 | -$36.75K | GRANT | 464.96% | 6.61K | Mar 02 | View |
| Mar 04, 2022 | Massimiliano Colao | CHIEF COMMERCIAL OFFICER | 5.29K | $12.01 | -$38.49K | GRANT | 64.57% | 13.49K | Mar 02 | View |
| Mar 04, 2022 | Peter Greenleaf | CHIEF EXECUTIVE OFFICER | 19.23K | $12.01 | -$108.91K | GRANT | 140.02% | 32.97K | Mar 02 | View |
| Mar 04, 2022 | Neil Solomons | CHIEF MEDICAL OFFICER | 3.65K | $12.01 | -$58.20K | GRANT | 4.19% | 90.95K | Mar 02 | View |
| Mar 04, 2022 | Robert Bindert Huizinga | EVP RESEARCH | 3.65K | $12.01 | -$58.24K | GRANT | 5.55% | 69.38K | Mar 02 | View |
| Jan 04, 2022 | Joseph P Hagan | DIRECTOR | 0.00 | $13.84 | -$700.45K | SELL-OPTIONS | 0.00% | 3.50K | Jan 03 | View |
| Dec 15, 2021 | Jill Leversage | DIRECTOR | 1.60K | $20.04 | $32.06K | BUY | 43.24% | 5.30K | Dec 13 | View |
| Nov 12, 2021 | Michael Robert Martin | CHIEF BUSINESS OFFICER | -121.00K | $24.31 | -$4.00M | SELL | -68.42% | 55.86K | Nov 09 - Nov 11 | View |
| Nov 12, 2021 | Neil Solomons | CHIEF MEDICAL OFFICER | -50.00K | $17.80 | -$6.40M | SELL | -36.42% | 87.30K | Nov 09 - Nov 11 | View |
| Nov 03, 2021 | Neil Solomons | CHIEF MEDICAL OFFICER | 0.00 | $18.47 | -$1.19M | SELL-OPTIONS | 0.00% | 137.30K | Nov 01 | View |
| Nov 03, 2021 | Michael Robert Martin | CHIEF BUSINESS OFFICER | 0.00 | $17.42 | -$1.28M | SELL-OPTIONS | 0.00% | 176.86K | Nov 01 | View |
| Oct 26, 2021 | Robert Bindert Huizinga | EVP RESEARCH | -35.00K | $16.48 | -$3.56M | SELL | -34.75% | 65.73K | Oct 25 | View |
| Sep 22, 2021 | Robert Bindert Huizinga | EVP RESEARCH | -5.36K | $13.42 | -$701.82K | SELL | -5.06% | 100.73K | Sep 21 | View |
| Sep 22, 2021 | Michael Robert Martin | CHIEF BUSINESS OFFICER | 0.00 | $15.16 | -$1.92M | SELL-OPTIONS | 0.00% | 176.86K | Sep 20 - Sep 21 | View |
| Sep 16, 2021 | Michael Robert Martin | CHIEF BUSINESS OFFICER | 0.00 | $13.54 | -$725.02K | SELL-OPTIONS | 0.00% | 176.86K | Sep 14 | View |
| Sep 14, 2021 | Michael Robert Martin | CHIEF BUSINESS OFFICER | 0.00 | $12.68 | -$1.89M | SELL-OPTIONS | 0.00% | 176.86K | Sep 10 - Sep 14 | View |
| Sep 14, 2021 | Robert Bindert Huizinga | EVP RESEARCH | -32.50K | $21.15 | -$687.33K | SELL | -23.45% | 106.09K | Sep 10 - Sep 14 | View |
| Sep 14, 2021 | Neil Solomons | CHIEF MEDICAL OFFICER | 0.00 | $11.52 | -$2.50M | SELL-OPTIONS | 0.00% | 137.30K | Sep 10 - Sep 13 | View |
| Sep 08, 2021 | Michael Robert Martin | CHIEF BUSINESS OFFICER | -7.50K | $18.10 | -$135.75K | SELL | -4.07% | 176.86K | Sep 07 | View |
| Sep 08, 2021 | Robert Bindert Huizinga | EVP RESEARCH | -5.00K | $18.30 | -$91.50K | SELL | -3.48% | 138.59K | Sep 07 | View |
| Aug 27, 2021 | Michael Robert Martin | CHIEF BUSINESS OFFICER | -22.50K | $17.81 | -$400.73K | SELL | -10.88% | 184.36K | Aug 26 | View |
| Aug 26, 2021 | Neil Solomons | CHIEF MEDICAL OFFICER | -5.00K | $15.85 | -$79.25K | SELL | -3.51% | 137.30K | Aug 25 | View |
| Aug 10, 2021 | Neil Solomons | CHIEF MEDICAL OFFICER | -45.00K | $16.03 | -$721.35K | SELL | -24.03% | 142.30K | Aug 09 | View |
| Aug 10, 2021 | Michael Robert Martin | CHIEF BUSINESS OFFICER | -5.00K | $16.01 | -$80.05K | SELL | -2.36% | 206.86K | Aug 09 | View |
| Jul 29, 2021 | Michael Robert Martin | CHIEF BUSINESS OFFICER | -5.00K | $13.86 | -$69.30K | SELL | -2.31% | 211.86K | Jul 28 | View |
| Jun 23, 2021 | Michael Robert Martin | CHIEF BUSINESS OFFICER | -5.00K | $13.76 | -$68.80K | SELL | -2.25% | 216.86K | Jun 22 | View |
| May 13, 2021 | Hector MacKayDunn | DIRECTOR | 4.50K | $11.23 | $50.53K | BUY | 300.00% | 6.00K | May 11 - May 12 | View |
| May 12, 2021 | Matthew Maxwell Donley | EX VP, INTERN'L OPERATIONS | 9.90K | $10.07 | $99.74K | BUY | ∞ | 9.90K | May 11 | View |
| May 12, 2021 | Peter Greenleaf | CHIEF EXECUTIVE OFFICER | 5.13K | $10.71 | $54.89K | BUY | 61.54% | 13.45K | May 11 | View |
| May 12, 2021 | Jill Leversage | DIRECTOR | 2.50K | $10.96 | $27.39K | BUY | 208.33% | 3.70K | May 11 | View |
| May 11, 2021 | Joseph M Miller | CHIEF FINANCIAL OFFICER | 1.00K | $9.74 | $9.74K | BUY | ∞ | 1.00K | May 11 | View |
| Mar 15, 2021 | Neil Solomons | CHIEF MEDICAL OFFICER | 0.00 | $8.26 | -$418.80K | SELL-OPTIONS | 0.00% | 187.30K | Mar 12 | View |
| Mar 09, 2021 | George M. Milne Jr., Ph.D. | DIRECTOR | 5.00K | $13.00 | $65.00K | BUY | 12.50% | 45.00K | Mar 05 | View |
| Feb 02, 2021 | Jill Leversage | DIRECTOR | 1.60K | $16.03 | $25.65K | BUY | 266.67% | 2.20K | Jan 29 | View |
| Jan 29, 2021 | Stephen P Robertson | EVP, GENERAL COUNSEL | 900.00 | $16.14 | $14.53K | BUY | 49.45% | 2.72K | Jan 28 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.